Careful editorial coverage of longevity and immune-support peptides, including mitochondrial and antimicrobial compounds, with realistic framing and evidence context.
7 articles
Epitalon dosing clarity comes from understanding what the real human routines show—short courses, route-specific protocols, and why one settled U.S. standard still doesn't exist.
MOTS-c has finally entered human efficacy testing in the exact metabolic scenario that drove years of interest. A recruiting Phase 2a trial means the peptide's metabolism story is now being proven in real people, not just lab research.
LL-37 is one of the more intriguing longevity-and-immune-support peptides because it is already part of your biology and keeps gaining a sharper mechanistic story.
Thymosin alpha-1 is one of the few immune-support peptides with recent human data that feels concrete.
LL-37 now has a sharper immune story: a 2025 paper links it to cGAMP transport, STING signaling, and interferon-based antiviral activity. That makes the peptide easier to understand in longevity circles, even if the practical evidence is still early.
A grounded review of Epitalon for longevity-minded you: what it is, why it keeps showing up in serious peptide conversations, what the current evidence can and cannot support, and what to know about safety and sourcing before you go further.
MOTS-c dosage is still more routine question than fixed standard. Here's how longevity-focused dosing conversations usually work, what the current evidence actually supports, and why timing, cycle length, and injection setup matter more than a single number.
A longevity-focused peptide with durable anti-aging curiosity and clearly experimental evidence boundaries.
The most clinically grounded immune-support peptide in the site taxonomy, with stronger evidence than most peers in the topic.
A rising mitochondrial-derived peptide with strong metabolic and longevity crossover appeal.
An antimicrobial peptide with strong immune relevance and a natural bridge into healing and repair questions.